Our siRNA conjugate services support biotech companies, pharmaceutical research teams, CROs, academic laboratories, and platform developers working on RNA interference programs that need more than standard duplex synthesis. siRNA conjugates combine a silencing duplex with a targeting ligand, lipophilic group, peptide, antibody-directed element, aptamer, or polymer-associated design so the construct is better aligned with serum stability, tissue exposure, and cellular uptake than free siRNA alone. In current development practice, conjugate programs are usually planned together with strand-level chemistry such as 2′-OMe, 2′-F, terminal phosphorothioate protections, and defined overhang or phosphorylation patterns rather than treating conjugation as a separate add-on step.
Our platform integrates target and sequence review, conjugation strategy selection, linker planning, custom synthesis, purification, duplex preparation, analytical characterization, and research-stage functional support for siRNA conjugates across GalNAc, cholesterol, peptide, antibody, aptamer, folate, polymer, and nanoparticle-linked formats. By connecting siRNA design logic with practical conjugation chemistry and downstream assay requirements, we help teams reduce redevelopment cycles, compare delivery hypotheses more efficiently, and move forward with materials that are better defined for nonclinical RNAi workflows.
Targeted Uptake Decisions: The first challenge is rarely "can we synthesize the conjugate?" but rather "which conjugate format actually matches the tissue and cell-entry problem?" GalNAc remains the best-established direct-conjugate route for hepatocyte uptake through ASGPR, while extrahepatic programs often require broader ligand screening and a more experimental delivery strategy. Our team helps clients define whether a project is best served by GalNAc-siRNA conjugates, lipophilic constructs, receptor-binding ligands, or a more complex carrier-associated format.
Endosomal Escape Risk: Productive uptake is not the same as productive silencing. For many siRNA delivery systems, endosomal entrapment remains a major bottleneck, so projects fail when conjugate selection is based only on binding or internalization data. We build development plans that examine intracellular trafficking, release expectations, and whether a direct conjugate should be compared against peptide-, polymer-, or nanoparticle-enabled alternatives from our drug delivery platform.
Duplex Architecture and Off-Target Control: Conjugated siRNA performance depends on guide/passenger orientation, seed-region risk, strand asymmetry, terminal placement, and how chemical stabilization is distributed across the duplex. We help clients align conjugation plans with siRNA design services, ensuring that potency, passenger-strand suppression, stability, and assay compatibility are evaluated together rather than in separate workstreams.
Linker and Attachment-Site Effects: Conjugation site, branching position, and linker composition can materially change albumin association, self-assembly behavior, steric burden, and overall activity. This is especially important for lipidic and multivalent constructs, where a good sequence can underperform because the attachment logic was chosen too late or optimized only for synthetic convenience. We support route selection for 3′ and 5′ terminal attachment, branched linkers, cleavable spacers, and spacer chemistries that preserve duplex integrity.
Purification and Analytical Confidence: Conjugated siRNA introduces more structural complexity than standard duplex RNA, including incomplete coupling, side products, altered hydrophobicity, and duplex-handling challenges. Our workflows cover purification strategy, identity confirmation, purity review, duplex preparation, and project-specific reporting so research teams can compare candidates using well-characterized material rather than loosely defined "delivery-ready" constructs. We can also coordinate with siRNA interference detection services when downstream silencing assessment is part of the project scope.
Our siRNA conjugate services are structured for teams that need coordinated support from sequence planning through conjugation, purification, and analytical release. We support direct-conjugate and carrier-associated projects intended for discovery, nonclinical evaluation, mechanism studies, delivery screening, and platform comparison.
Rather than treating conjugation as a simple labeling exercise, we integrate strand chemistry, linker placement, duplex behavior, and application-specific testing needs so clients can make better decisions on construct selection, scale-up feasibility, and next-step study design.
The table below helps research teams compare common siRNA conjugate formats by delivery logic, technical strengths, and likely development risks. It is most useful at the stage where teams are deciding whether to prioritize a direct conjugate, a receptor-targeting strategy, or a more complex carrier-linked construct.
| Conjugate Format | Main Delivery Logic | Typical Attachment Strategy | Key Advantages | Main Watchpoints | Best-Fit Research Uses |
| GalNAc-siRNA | Receptor-mediated hepatocyte uptake through ASGPR | Branched GalNAc ligand attached at a terminal siRNA position with defined spacer chemistry | Strong liver targeting logic, no large carrier requirement, well-established direct-conjugate workflow | Limited extrahepatic utility, endosomal escape still matters, ligand architecture affects performance | Liver-targeted knockdown studies, PK/PD comparison, hepatocyte uptake evaluation |
| Cholesterol or Lipid-siRNA | Modulate membrane interaction, protein association, and tissue exposure through hydrophobic design | Terminal lipid or cholesterol conjugation with spacer and branch-point control | Flexible format for exposure tuning, useful for local and extrahepatic delivery exploration | Aggregation, altered biodistribution, purification burden, attachment-site sensitivity | Tissue-retention studies, intracellular trafficking work, structure-function optimization |
| Peptide-siRNA | Use peptide sequence to promote uptake, receptor interaction, or intracellular release | Covalent linkage through terminal handles, cleavable linkers, or spacer-enabled peptide attachment | Broad design flexibility and useful for mechanistic screening | Proteolysis risk, charge-related handling issues, higher synthesis complexity | Cell uptake studies, endosomal-assist concepts, receptor-directed screening |
| Antibody or Aptamer-siRNA | Cell-selective recognition through higher-affinity targeting ligands | Controlled conjugation through reactive handles and linker architectures that preserve binding | Strong targeting hypothesis generation and receptor-specific screening value | Steric effects, multicomponent heterogeneity, release design complexity | Targeted uptake validation, receptor biology studies, cell-specific delivery exploration |
| Folic Acid-siRNA | Small-molecule ligand targeting for folate receptor-associated uptake studies | Terminal ligand coupling with spacer optimization to reduce steric interference | Compact design and straightforward ligand concept for receptor-screening workflows | Receptor dependence, competitive uptake effects, assay-context sensitivity | Receptor-focused cell models, exploratory tumor-cell uptake studies, ligand comparison panels |
| Polymer or Nanoparticle-Linked siRNA | Increase multivalency, payload handling, and delivery control through a larger carrier system | Conjugated or associated siRNA with charge-balanced polymers, particles, or dynamic assemblies | More room for formulation engineering and endosomal escape design | Higher complexity, broader CMC burden, batch comparability and release characterization challenges | Extrahepatic delivery screening, platform comparison, carrier-assisted nonclinical studies |
Successful siRNA conjugate programs depend on more than sequence selection. The assessment matrix below summarizes the main technical review areas that help teams connect silencing intent with ligand choice, linker design, manufacturability, and downstream decision quality.
| Assessment Category | What We Evaluate | Why It Matters | Typical Outputs | Stage Alignment |
| Target & Duplex Review | Target region, strand orientation, overhang design, seed-region risk, and intended knockdown context | Prevents delivery work from being built on a weak or off-target-prone siRNA sequence | Candidate list, strand annotation, control recommendations | Discovery |
| Modification Map Planning | Placement of 2′-OMe, 2′-F, phosphorothioate ends, phosphorylation, and other stabilizing features | Balances stability, potency, duplex handling, and conjugation compatibility | Strand-by-strand chemistry map | Discovery |
| Ligand Selection Review | Suitability of GalNAc, lipid, peptide, antibody, aptamer, folate, or polymer-based strategies | Aligns the conjugate class with the real biological delivery problem | Recommended format shortlist and rationale | Discovery / Early Development |
| Linker & Attachment Design | Terminal placement, spacer length, branching site, cleavable versus noncleavable logic | Reduces steric interference and avoidable activity loss after conjugation | Conjugation route proposal and attachment map | Early Development |
| Purification Strategy | Impact of hydrophobicity, multicomponent structure, and side products on purification workflow | Helps teams obtain analytically credible material for fair candidate comparison | Purification plan and release criteria | Early Development |
| Biophysical Handling Review | Solubility, aggregation tendency, duplex preparation, storage, and reconstitution behavior | Prevents assay variability that comes from handling failure rather than sequence quality | Handling recommendations and risk notes | Early Development |
| Analytical Confirmation | Identity, purity, conjugate integrity, strand confirmation, and batch documentation | Ensures material released for research use is structurally understood | QC summary and analytical report | Development |
| Functional Screening Plan | Uptake testing, knockdown assay fit, candidate comparison logic, and control strategy | Turns a chemistry program into a decision-ready screening workflow | Assay plan and next-step recommendations | Development |
This workflow reflects how research teams typically engage us for siRNA conjugate design, synthesis, purification, and analytical handoff. It is structured for discovery, platform development, and nonclinical evaluation programs rather than clinical use.
We review target information, species, desired knockdown context, tissue or cell-type objective, preferred conjugate class, assay format, quantity needs, and timeline constraints. This step ensures the conjugate format is selected for the real experimental problem instead of being chosen only because it is familiar or easy to order.
Our team defines the siRNA duplex architecture, strand modification pattern, conjugation site, and ligand shortlist. When appropriate, we also recommend parallel design of unconjugated and differently conjugated controls so structure-function differences can be interpreted more clearly.
We finalize linker strategy, reactive handles, synthesis route, purification targets, and analytical expectations before execution. This planning stage is especially important for hydrophobic, peptide-bearing, or multicomponent constructs that can behave very differently from standard duplex siRNA during manufacturing.
The project proceeds through strand synthesis, modification incorporation, conjugation, duplex preparation if required, and purification using fit-for-purpose workflows. We control the process to minimize incomplete coupling, excess free ligand, and other issues that can compromise later screening results.
We confirm identity, purity, and conjugate integrity and can align the release package with downstream uptake, silencing, or comparative screening studies. When a client is comparing multiple formats, results are organized so chemistry differences and functional outcomes can be linked more directly.
Clients receive the agreed material package, sequence and modification documentation, handling guidance, and technical notes for follow-on work. We can then support next-stage optimization, additional conjugate classes, scale adjustment, or transfer into broader RNAi and delivery development workflows.
siRNA conjugate projects usually fail at the interface between RNA design, conjugation chemistry, and delivery biology. Our service model is built to manage that interface directly, helping clients move from concept to research-ready material with clearer technical logic and fewer avoidable redesign cycles.
siRNA conjugates are used when researchers need more control over delivery behavior, target-cell exposure, or construct tracking than standard duplex siRNA can provide. Our services support the following research and development directions.
Whether you need a GalNAc-siRNA construct for hepatocyte studies, a cholesterol-conjugated duplex for exposure optimization, a peptide-linked candidate for uptake screening, or a broader comparison across multiple siRNA conjugate classes, our team can help you define a technically credible path forward. We support sequence review, conjugation strategy selection, synthesis, purification, analytical release, and downstream research planning so your project moves with clearer structure and better-quality materials. If your team is evaluating which siRNA conjugate format is most appropriate for a target, tissue, or assay system, contact us to discuss your project scope and build a fit-for-purpose development plan.
siRNA conjugates provide enhanced stability against nuclease degradation, improved cellular uptake through targeted ligands, reduced off-target effects, and optimized pharmacokinetic profiles for research applications.
Ligand selection is based on receptor expression profiles of target cells, binding affinity characteristics, internalization efficiency, and compatibility with siRNA structure and function requirements.
Strategic attachment points, optimized linker chemistry, and controlled stoichiometry preserve siRNA silencing activity while enabling efficient cellular delivery and intracellular release.
